Quinagolide
Quinagolide (INN, BAN; brand name Norprolac) is a selective D2 receptor agonist that is used to reduce elevated levels of prolactin (hyperprolactinemia).[1] It has also been found to be effective in the treatment of breast pain.[2]
![]() Structure without stereochemistry | |
| Clinical data | |
|---|---|
| Trade names | Norprolac |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H33N3O3S |
| Molar mass | 395.56 g/mol g·mol−1 |
InChI
| |
| | |
Stereochemistry
Quinagolide is a racemate composed of the following two enantiomers:[3]
| Enantiomeres of Quinagolide | |
|---|---|
![]() (+)-Quinagolid CAS number: 140630-79-1 |
![]() (-)-Quinagolid CAS number: 140630-80-4 |
See also
References
- Antonella Di Sarno; Maria Luisa Landi; Paolo Marzullo; Carolina Di Somma; Rosario Pivonello; Gaetana Cerbone; Gaetano Lombardi; Annamaria Colao (July 2000). "The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas". Clinical Endocrinology. 53 (1): 53–60. doi:10.1046/j.1365-2265.2000.01016.x. PMID 10931080.
- Alfonso M Pluchinotta (20 April 2015). The Outpatient Breast Clinic: Aiming at Best Practice. Springer. pp. 167–. ISBN 978-3-319-15907-2.
- Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 - Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 214.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.
-Quinagolid_Structural_Formula_V1.svg.png)
-Quinagolid_Structural_Formula_V1.svg.png)
-Quinagolid_Structural_Formula_V1.svg.png)